Author Profile

Lonza to Sell Capsule & Health Ingredients Unit to Lone Star for $3B
Lonza will retain a 40% equity position in the business. read more
Sanofi Bets $1.53B on Sino Biopharm Oral JAK/ROCK Inhibitor
The drug is approved in China as treatment for myelofibrosis, but Sanofi wants to explore its potential to treat cGVHD. read more
Digital, Continuous and Data-Rich
Advances in technologies, data, and development strategies are reshaping how oral solid dosage drugs are designed and manufactured, with a clear emphasis on lowering cost, shortening timelines, and improving quality and ... read more
Aardvark Pauses Prader-Willi Trials in Wake of Cardiac Concerns
The company observed reversible cardiac issues in healthy volunteers who were taking above target therapeutic doses. read more
Novo Nordisk to Invest $510M in Ireland Tableting Facility for Oral GLP-1s
The company will use the investment to turn Ireland into a hub for producing high-quality oral medications to distribute outside the U.S. read more
Merck Releases Data from Phase 3 Trials for HIV Drug Regimen
If approved, DOR/ISL may provide an important new option to help meet the evolving treatment needs of people living with HIV. read more
Genentech Releases Positive Phase 3 Data for Oral BTK Inhibitor
Results are comparable to another phase 3 trial, solidifying the oral drug’s potential to become the first BTK inhibitor for relapsing multiple sclerosis. read more
Vanda Gets FDA Nod for Schizophrenia, Bipolar Antipsychotic Tablet
Bysanti, an atypical antipsychotic, is expected to become commercially available in Q3 2026. read more
FDA Issues CRL for Disc Rare Disease Drug, Despite National Priority Voucher
The FDA says it needs to see the results of the phase 3 Apollo study, which is currently in progress, before it is able to come to a decision. read more
Altesa BioSciences Closes $75M Series B to Advance Oral COPD Drug
The drug saw positive results in a previous study, reducing symptoms and the duration of illness in COPD patients with a rhinovirus infection. read more
Sanofi Expands India Global Capability Center
The expansion will create one of the top three pharmaceutical GCCs in India. read more
Angles of Insight: Exploring the Geometry of XRPD
X-ray powder diffraction provides a window into the crystalline structure, enabling developers to identify and quantify phases with precision. read more
PTC Withdraws FDA Submission for Duchenne Drug
Per the FDA, Translarna does not meet the threshold of evidence of effectiveness and is unlikely to receive approval. read more
FDA Removes 'Black Box' Label from Menopause Drugs
The action removes risk statements related to cardiovascular disease, breast cancer and probable dementia. read more
Compass Psychedelic Shows Efficacy, Durability in Treatment-Resistant Depression
Based on the data, Compass has submitted a request for a meeting with the FDA to discuss a rolling submission and review. read more
IMA Buys ProSys to Boost Isolation Offerings
Ireland-based ProSys will continue to operate as an independent business. read more
Novo Threatens Legal Action Over Hims Knockoff Wegovy Pill
The drugmaker has cited concerns about the safety, quality and effectiveness of the compounded GLP-1. read more
White House Launches TrumpRx DTC Prescription Drug Portal
Currently, TrumpRx offers 43 drugs from five companies to treat a variety of conditions. read more
FDA Hands Aquestive CRL for Oral Allergy Drug, Citing Packaging Issues
Issues with opening the pouch and film placement could be dangerous for patients suffering from anaphylaxis. read more
Bayer Factor XIa Inhibitor Cuts Stroke Risk by 26%
The trial is the first phase 3 study of a Factor XIa inhibitor which demonstrated superiority in reducing recurrent ischemic stroke. read more

January/February 2026

2026 Annual Buyer’s Guide
View Issue

Subscribe to Magazine

Get started here for your complimentary print or digital subscription

Get started here for your complimentary print or digital subscription
Sign up Now »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox!